Comprehensive analysis of immune-related prognostic genes in the tumour microenvironment of hepatocellular carcinoma

被引:1
作者
Gao, Weike [1 ]
Li, Luan [1 ]
Han, Xinyin [3 ,4 ]
Liu, Siyao [5 ]
Li, Chengzhen [2 ]
Yu, Guanying [2 ]
Zhang, Lei [2 ]
Zhang, Dongsheng [1 ]
Liu, Caiyun [1 ]
Meng, Erhong [5 ]
Hong, Shuai [5 ]
Wang, Dongliang [5 ]
Guo, Peiming [2 ]
Shi, Guangjun [1 ]
机构
[1] Qingdao Univ, Dept Hepatobiliaty & Pancreat Surg, Qingdao Municipal Hosp, Qingdao 266000, Shandong, Peoples R China
[2] Shandong Univ, Dept Gastrointestinal Surg 2, Jinan Cent Hosp, 105 Jiefang Rd, Jinan 250013, Shandong, Peoples R China
[3] Chinese Acad Sci, Comp Network Informat Ctr, Beijing 100190, Peoples R China
[4] Univ Chinese Acad Sci, Beijing 100190, Peoples R China
[5] ChosenMed Technol Beijing Co Ltd, Beijing 100176, Peoples R China
关键词
Hepatocellular carcinoma; Biomarker; Prognostic; Immune; TGF-BETA; CANCER; EXPRESSION; NIVOLUMAB; IPILIMUMAB; IDENTIFICATION; ANTI-PD-1; BLOCKADE; CELLS; PEMBROLIZUMAB;
D O I
10.1186/s12885-021-08052-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundThe mortality rate of hepatocellular carcinoma (HCC) remains high worldwide despite surgery and chemotherapy. Immunotherapy is a promising treatment for the rapidly expanding HCC spectrum. Therefore, it is necessary to further explore the immune-related characteristics of the tumour microenvironment (TME), which plays a vital role in tumour initiation and progression.MethodsIn this research, 866 immune-related differentially expressed genes (DEGs) were identified by integrating the DEGs of samples from The Cancer Genome Atlas (TCGA)-HCC dataset and the immune-related genes from databases (InnateDB; ImmPort). Afterwards, 144 candidate prognostic genes were defined through weighted gene co-expression network analysis (WGCNA).ResultsSeven immune-related prognostic DEGs were identified using the L1-penalized least absolute shrinkage and selection operator (LASSO) Cox proportional hazards (PH) model, and the ImmuneRiskScore model was constructed on this basis. The prognostic index of the ImmuneRiskScore model was then validated in the relevant dataset. Patients were divided into high- and low-risk groups according to the ImmuneRiskScore. Differences in the immune cell infiltration of patients with different ImmuneRiskScore values were clarified, and the correlation of immune cell infiltration with immunotherapy biomarkers was further explored.ConclusionThe ImmuneRiskScore of HCC could be a prognostic marker and can reflect the immune characteristics of the TME. Furthermore, it provides a potential biomarker for predicting the response to immunotherapy in HCC patients.
引用
收藏
页数:16
相关论文
共 72 条
[1]  
[Anonymous], 2008, JNCI J NATL CANC I
[2]   ImmPort, toward repurposing of open access immunological assay data for translational and clinical research [J].
Bhattacharya, Sanchita ;
Dunn, Patrick ;
Thomas, Cristel G. ;
Smith, Barry ;
Schaefer, Henry ;
Chen, Jieming ;
Hu, Zicheng ;
Zalocusky, Kelly A. ;
Shankar, Ravi D. ;
Shen-Orr, Shai S. ;
Thomson, Elizabeth ;
Wiser, Jeffrey ;
Butte, Atul J. .
SCIENTIFIC DATA, 2018, 5
[3]   Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].
Brahmer, Julie ;
Reckamp, Karen L. ;
Baas, Paul ;
Crino, Lucio ;
Eberhardt, Wilfried E. E. ;
Poddubskaya, Elena ;
Antonia, Scott ;
Pluzanski, Adam ;
Vokes, Everett E. ;
Holgado, Esther ;
Waterhouse, David ;
Ready, Neal ;
Gainor, Justin ;
Aren Frontera, Osvaldo ;
Havel, Libor ;
Steins, Martin ;
Garassino, Marina C. ;
Aerts, Joachim G. ;
Domine, Manuel ;
Paz-Ares, Luis ;
Reck, Martin ;
Baudelet, Christine ;
Harbison, Christopher T. ;
Lestini, Brian ;
Spigel, David R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135
[4]   Potential of immunotherapy for hepatocellular carcinoma [J].
Breous, Ekaterina ;
Thimme, Robert .
JOURNAL OF HEPATOLOGY, 2011, 54 (04) :830-834
[5]   Stromal gene expression defines poor-prognosis subtypes in colorectal cancer [J].
Calon, Alexandre ;
Lonardo, Enza ;
Berenguer-Llergo, Antonio ;
Espinet, Elisa ;
Hernando-Momblona, Xavier ;
Iglesias, Mar ;
Sevillano, Marta ;
Palomo-Ponce, Sergio ;
Tauriello, Daniele V. F. ;
Byrom, Daniel ;
Cortina, Carme ;
Morral, Clara ;
Barcelo, Carles ;
Tosi, Sebastien ;
Riera, Antoni ;
Attolini, Camille Stephan-Otto ;
Rossell, David ;
Sancho, Elena ;
Batlle, Eduard .
NATURE GENETICS, 2015, 47 (04) :320-U62
[6]   Targeting macrophages: therapeutic approaches in cancer [J].
Cassetta, Luca ;
Pollard, Jeffrey W. .
NATURE REVIEWS DRUG DISCOVERY, 2018, 17 (12) :887-904
[7]   Immunomodulatory TGF-β Signaling in Hepatocellular Carcinoma [J].
Chen, Jian ;
Gingold, Julian A. ;
Su, Xiaoping .
TRENDS IN MOLECULAR MEDICINE, 2019, 25 (11) :1010-1023
[8]   Integrative analysis of imaging and transcriptomic data of the immune landscape associated with tumor metabolism in lung adenocarcinoma: Clinical and prognostic implications [J].
Choi, Hongyoon ;
Na, Kwon Joong .
THERANOSTICS, 2018, 8 (07) :1956-1965
[9]   Smad-dependent and Smad-independent pathways in TGF-β family signalling [J].
Derynck, R ;
Zhang, YE .
NATURE, 2003, 425 (6958) :577-584
[10]   Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial [J].
El-Khoueiry, Anthony B. ;
Sangro, Bruno ;
Yau, Thomas ;
Crocenzi, Todd S. ;
Kudo, Masatoshi ;
Hsu, Chiun ;
Kim, Tae-You ;
Choo, Su-Pin ;
Trojan, Jorg ;
Welling, Theodore H., III ;
Meyer, Tim ;
Kang, Yoon-Koo ;
Yeo, Winnie ;
Chopra, Akhil ;
Anderson, Jeffrey ;
dela Cruz, Christine ;
Lang, Lixin ;
Neely, Jaclyn ;
Tang, Hao ;
Dastani, Homa B. ;
Melero, Ignacio .
LANCET, 2017, 389 (10088) :2492-2502